<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304913</url>
  </required_header>
  <id_info>
    <org_study_id>14-5953-BO</org_study_id>
    <nct_id>NCT02304913</nct_id>
  </id_info>
  <brief_title>Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy</brief_title>
  <acronym>OralAcu</acronym>
  <official_title>Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <brief_summary>
    <textblock>
      This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to
      sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of
      dysgeusia in cancer patients undergoing chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Taste disorders are frequent side effects in patients undergoing chemotherapy (CTX).
      Dysguesia has prevalence rates of 16% to 1000% during CTX with sometimes also persistent
      courses. Impact of dysguesia on appetite, body weight as well as health-related quality of
      life was shown. Until now, evidence for adequate treatment options is limited to specific
      diary recommendations. Acupuncture in the treatment of side effects of chemotherapy was
      investigated for nausea and xerostomia, but not for dysguesia. Therefore, this randomized
      controlled trial aims to investigate hypoglossal acupuncture in comparison to sham
      acupuncture and standard medical treatment (dietary recommendations) in the treatment of
      dysgeusia in cancer patients undergoing chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysgeusia (Phantogeusia) (NRS - Numeric Rating Scale)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysgeusia (Parageusia, Hypogeusia, Hypergeusia) (NRS - Numeric Rating Scale)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Xerostomia (NRS - Numeric Rating Scale)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stomatitis (NRS - Numeric Rating Scale)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite (NRS - Numeric Rating Scale)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impairment (NRS - Numeric Rating Scale)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (free text)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Expectancy and Credibility (TCS - Treatment Credibility Scale + BI - Blining Index)</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acupuncture</condition>
  <condition>Taste Disorders</condition>
  <condition>Dysgeusia</condition>
  <condition>Chemotherapy</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Hypoglossal acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham acupuncture</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary recommendations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoglossal acupuncture</intervention_name>
    <arm_group_label>Hypoglossal acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham acupuncture</intervention_name>
    <arm_group_label>Sham acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary recommendations</intervention_name>
    <arm_group_label>Dietary recommendations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initial treatment with platinum-containing or taxane-based CTX (regardless of the the
             length of the CTX cycle)

          -  Breast cancer

          -  Phantogeusia (on average ≥4 NRS)

          -  Willingness to participate in the study and written informed consent

        Exclusion Criteria:

          -  Severe stomatitis

          -  Dysgeusia before the CTX based on neurological diseases, diabetes, or the ingestion of
             drugs with taste disorders as side effects

          -  Leucopenia/neutropenia

          -  Intake of anticoagulants

          -  Smoking

          -  Severe physical or mental comorbidity (due to which the patient is unable to
             participate in the study)

          -  Participation in other CAM treatments within the integrative oncology care

          -  Participation in other studies on the effectiveness of interventions for oral
             complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustav Dobos, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal and Integrative Medicine | Kliniken Essen-Mitte | Faculty of Medicine | University of Duisburg-Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidemarie Haller, PhD</last_name>
    <phone>004920117425044</phone>
    <email>h.haller@kem-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Holger Cramer, PhD</last_name>
    <email>h.cramer@kem-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecology &amp; Gynecologic Oncology, Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidemarie Haller, PhD</last_name>
      <phone>004920117425044</phone>
      <email>h.haller@kem-med.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Heidemarie Haller</investigator_full_name>
    <investigator_title>Postdoctoral Research Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Taste Disorders</mesh_term>
    <mesh_term>Dysgeusia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

